CBP-307 is a novel and selective second generation S1P1 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease and psoriasis. CBP-307 exhibited excellent safety features and potent T cell modulation activity as well as optimal pharmacokinetics and pharmacodynamics profiles, demonstrating the best-in-class potential. CBP-307 is in phase I clinical trials by Suzhou Connect for the treatment of autoimmune diseases.
MedKoo Cat#: 530561
Name: CBP-307
CAS#: Unknown
Chemical Formula: C24H26FN3O3
Exact Mass: 423.1958
Molecular Weight: 423.49
Elemental Analysis: C, 68.07; H, 6.19; F, 4.49; N, 9.92; O, 11.33
The following data is based on the product molecular weight 423.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
